Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9980 | 0.81 | PDGFRB (0.38) | PIK3CAGRM5PDGFRBPDGFRA | |
| SCHEMBL12467748 | 0.77 | UHRF1 (0.31) | — | |
| SCHEMBL12466486 | 0.77 | MAPT (0.49) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL23537645 | 0.76 | — | — | |
| SCHEMBL91467 | 0.72 | MAPT (0.55) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL31015194 | 0.71 | CHRNB2 (0.38) | GRM5PDGFRBPDGFRA | |
| SCHEMBL3680715 | 0.71 | ACACB (0.34) | — | |
| SCHEMBL8986074 | 0.70 | MAPT (0.56) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL1349094 | 0.70 | HSP90AA1 (0.35) | GRM5 | |
| SCHEMBL29540711 | 0.70 | MAPT (0.56) | MAPTCASP1AURKATTKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668179-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-08-16 | — | — | EP | disclosed |
| EP-2668179-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-08-16 | — | — | EP | disclosed |
| EP-2668178-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2668178-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2668178-A1 | NEW 5-ALKYNYL-PYRIDINES | Boehringer Ingelheim International GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| US-8598157-B2 | 5-alkynyl-pyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-03 | — | — | US | disclosed |
| US-8466162-B2 | 5-alkynyl-pyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466162-B2 | 5-alkynyl-pyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466162-B2 | 5-alkynyl-pyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20130023533-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023533-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023519-A1 | 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023519-A1 | 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| EP-2546249-A1 | 5-Alkynyl-pyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012101184-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023519-A1 | 5-ALKYNYL-PYRIDINES | PIK3CA, PTEN, PIK3CD | MAPT 4286/4885CASP1 1349/4885AURKA 1021/4885 |
| US-20130023533-A1 | NEW 5-ALKYNYL-PYRIDINES | PIK3CA, MKI67, PIK3CD | MAPT 4462/4885CASP1 1233/4885AURKA 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.